retatrutide clinical trial phase retatrutide trials efficacy (RETA) is one of the most promising investigational peptides in obesity research— retatrutide clinical trials status 2025

In stock (can be backordered) Retatrutide 30mg Research Overview Retatrutide 30mg is a next-generation multi-agonist peptide investigated in metabolic research for its activity at GLP-1, GIP, and glucagon receptors

*Benefits as shown are reported in ingredient-specific studies

Retatrutide remains investigational, with Phase 3 trials ongoing and potential approval not expected until mid-2026 or 2027 at the earliest

GLP-1 receptor agonists mimic a hormone in the body that helps regulate blood sugar and appetite

Cost Comparisons Benefits of Compounded GLP-1 Medications Affordability: More cost-effective than commercial options, especially for those paying out of pocket

Ozempic face compresses similar structural changes into months, which is why patients often describe looking significantly older than before they started their weight loss journey